JENNA WAGENBLATT: Open Payments
NPI 1578286936 · LIVERPOOL, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 45 payments from 17 companies in 2025. Trend: 2023 $427 · 2024 $1,363 · 2025 $989
Food & beverage: $989
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $151 |
| Madrigal Pharmaceuticals | 4 | $140 |
| ABBVIE INC. | 6 | $98 |
| Astellas Pharma US Inc | 3 | $85 |
| Lilly USA, LLC | 4 | $81 |
| Corcept Therapeutics | 3 | $71 |
| GlaxoSmithKline, LLC. | 4 | $70 |
| KYOWA KIRIN, INC. | 2 | $52 |
| Novo Nordisk Inc | 3 | $48 |
| PFIZER INC. | 2 | $34 |
Products named: CAPLYTA, REZDIFFRA, Veozah, Korlym, TRELEGY ELLIPTA, UBRELVY, CRYSVITA, Flexitouch Plus.
Industry payments across NY — which companies pay providers there.
